SUMMARY A monoclonal antibody, produced by peptide immunisation was used to detect the distribution of p62cImYc by immunohistology in normal and coeliac small intestinal mucosa. The effect of gluten in four treated coeliac patients was investigated by taking serial jejunal biopsy specimens for six hours after a 1Og oral gluten challenge. There was a progressive increase in p62c/mYc staining intensity in the villus enterocytes extending to the crypts, which accompanied the classical morphological changes occurring in the mucosa.
Coeliac disease is characterised by a small intestinal villus atrophy that improves on treatment with a gluten free diet. The rate of differentiation and control of the cell cycle of small intestinal enterocytes in this condition differs from that of normal controls,' although the pathogenesis is unknown.
Recombinant DNA techniques have permitted the identification of DNA sequences termed cellular oncogenes, including c-myc, which are the cellular homologues of genes first identified in retroviruses,2 and which have vital regulating roles in the control of cell growth.3 Oncogene products can be detected by immunohistology, permitting comparisons of their quantity and distribution,4 which may elucidate their role in the development of cellular pathology.
A monoclonal antibody to the c-myc gene product p62c/mYc, constructed by peptide immunisation techniques,S 6was used to assess changes in the p62c1mYc content of the small bowel mucosa from non-coeliac controls, treated and untreated coeliac patients, and four treated coeliac patients subjected to a gluten challenge.
Patients and methods
Jejunal biopsy specimens taken from controls and treated and untreated coeliac patients as part of their diagnostic management, were fixed in 10% formalin and processed to 5 pm sections.
The diagnosis of coeliac disease was made from the Accepted for publication 25 September 1986 presence of the classical changes in the morphology of peroral small intestinal jejunal biopsy specimens. Jejunal subtotal villus atrophy, which improved on treatment with a gluten free diet and recurred following a gluten challenge, was considered to be diagnostic of coeliac disease.
PATIENTS

Controls
Five subjects had a jejunal biopsy for diagnostic purposes; jejunal mucosal morphology was normal with no evidence of coeliac disease. The diagnoses in these patients were irritable bowel syndrome (four cases) and unexplained short stature (one case).
Untreated coeliac patients Five patients had untreated coeliac disease; jejunal biopsy specimens showed subtotal villus atrophy. 
Discussion
The presence of low amounts of the c-myc oncogene product in maturing jejunal enterocytes from control subjects and treated coeliac patients suggests that the c-myc oncogene may participate in small intestinal cellular differentiation. In untreated coeliac disease the presence of increased amounts of the c-myc oncogene product both in the nucleus and cytoplasm of enterocytes of the upper third of the stunted villi suggests that the c-myc oncogene may participate in the premature senescence and desquamation of these cells. A gluten challenge in four treated coeliac patients induced an abnormal staining pattern within two hours of the challenge when the villus morphology was deteriorating. This suggests that the cmyc oncogene may participate in the premature death of these small intestinal villus enterocytes and therefore the pathogenesis of this disease.
One of the typical features of untreated coeliac disease is small intestinal villus atrophy, in which the -crypts are elongated and increased in diameter. The crypts contain enterocytes with an increased mitotic rate in the lower third compared with that of controls.lo
The molecular mechanisms entailed in the control of cell proliferation and differentiation of the small bowel have been difficult to study. Advances in genetic engineering and monoclonal antibody technology have enabled antibodies to be raised against the protein products of oncogenes. These techniques permit an investigation of the molecular basis for the disruption of control mechanisms in several diseases.
Gastrointestinal cell renewal was examined with the rat small bowel mucosa as a model. This showed that as well as a stem cell component, most cell production takes place in the proliferative compartment at the crypt base, from which the immature cells migrate up into the maturation zone. As the cells enter this area they rapidly lose their capacity to divide and undergo differentiation, resulting in their emergence on to the villi. After a lifespan of three to five days in normal subjects the cells senesce and desquamate into the small bowel lumen." The careful regulation of cell division, maturation, and shedding must entail coordinated gene expression for it to continue with such precision.
Use of a metaphase arrest technique has shown that the cell cycle time (Tc) and mitotic duration (TM) in the normal small bowel mucosa is about 50 hours and one hour, respectively. 12 In coeliac disease there is an increase in the mitotic index due to an increased rate of cell division. Not only is there a change in the cell cycle time, but the cells fail to differentiate into mature cells.'3 Cell loss in coeliac disease, as measured by DNA from the washings from perfused segments of small bowel, shows a sixfold increase above normal.'4 There is a concomitant increase in cell production in untreated disease, due to a higher number of proliferating cells and a doubling of the rate of cell division.
The c-myc gene and its product p62cImYc have been implicated in the control of cell cycle activation and differentiation. The activation or expression of p62c/mYc, probably in combination with other oncogene products, is in part responsible for the increase in the rate of cell proliferation, decrease in cell cycle time, and abnormal differentiation. The true nature of the regulating mechanism, whereby gluten challenge results in an increase in the rate of cell loss, remains unknown. It is unlikely that such mechanisms operate only in coeliac disease, and other insults that result in a compensatory proliferation may produce similar changes. An oncogene product cascade system may have a role. It is known that p62c/mYc can partly replace the dependence of cells on other stimulating and growth mitogens such as platelet derived growth factor, epidermal growth factor, insulin, or steroids. '5 The c-myc protein product is a nuclear associated protein and has a role in the control of the cell cycle and differentiation, though its exact function remains to be determined. It is probable that the insult produced by gluten results in a number of oncogene products being over or inappropriately expressed. Overproduction or abnormal expression of p62c/mYc may play a part in the failure of the dividing cells in the small bowel mucosa to attain a fully differentiated state as well as preventing dividing cells from reentering Go, and therefore it may participate in the pathogenesis of coeliac disease.
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